Literature DB >> 18544943

New diagnostic method for liver fibrosis and cirrhosis.

Kwang-Hyub Han1, Ki Tae Yoon.   

Abstract

Liver fibrosis, i.e. excessive accumulation of extracellular matrix proteins, occurs in most types of chronic liver diseases. The prognosis and management of chronic liver diseases depend on the degree of liver fibrosis. Therefore, the assessment of liver fibrosis provides useful information not only for diagnosis but also for treatment planning. Although liver biopsy is still the gold standard for assessing hepatic fibrosis, it has some technical limitations and risks. Furthermore, the dynamic process of liver fibrosis resulting from progression and regression cannot be quantified by liver biopsy. Therefore, alternative, simple, reliable and noninvasive tests are needed to assess the stage of fibrosis. Several noninvasive direct and indirect serum markers able to predict the presence of significant fibrosis or cirrhosis in patients with chronic liver disease with considerable accuracy have been reported. However, since most of these markers require complicated calculations, clinical application is difficult. Transient elastography (FibroScan) is a new method for the evaluation of liver stiffness. The technique is based on changes in tissue elasticity induced by hepatic fibrosis. Liver stiffness measured by transient elastography is a noninvasive, reproducible and reliable method to assess hepatic fibrosis as well as to diagnose liver cirrhosis. Based on accumulating clinical data, clinical applications of elastography will increase in the near future. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18544943     DOI: 10.1159/000122594

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  19 in total

Review 1.  Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives.

Authors:  Beom Kyung Kim; James Fung; Man-Fung Yuen; Seung Up Kim
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

2.  TBX21 polymorphisms are associated with virus persistence in hepatitis C virus infection patients from a high-risk Chinese population.

Authors:  D Y Zhu; L F Jiang; X Z Deng; W Xiao; J P Pei; B J Li; C J Wang; J H Zhang; Q Zhang; Z X Zhou; W L Ding; X D Xu; M Yue
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-11       Impact factor: 3.267

3.  The relevance of Tim-3 polymorphisms and F protein to the outcomes of HCV infection.

Authors:  J P Pei; L F Jiang; X W Ji; W Xiao; X Z Deng; Z X Zhou; D Y Zhu; W L Ding; J H Zhang; C J Wang; K Jing
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-26       Impact factor: 3.267

4.  The antifibrotic effects of the novel compound gorse isoflavone alkaloid on chemical liver injury in rats.

Authors:  Yang-Wen Ai; Fang-Cheng Fan; Hua Liu; Xiao-Jie Shi; Ke-Qin Li; Qing-Shan Liu; Hui Jiang
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

5.  External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients.

Authors:  Beom Kyung Kim; Kwang Hyub Han; Jun Yong Park; Sang Hoon Ahn; Chae Yoon Chon; Ja Kyung Kim; Yong Han Paik; Kwan Sik Lee; Young Nyun Park; Do Young Kim
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

6.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

7.  FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B.

Authors:  Deping Ding; Hongbing Li; Ping Liu; Lingli Chen; Jian Kang; Yinhua Zhang; Deqiang Ma; Yue Chen; Jie Luo; Zhongji Meng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

Authors:  Beom Kyung Kim; Seung Up Kim; Hyon Suk Kim; Jun Yong Park; Sang Hoon Ahn; Chae Yoon Chon; In Rae Cho; Dong-Hoo Joh; Young Nyun Park; Kwang-Hyub Han; Do Young Kim
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

9.  Staging of hepatic fibrosis: comparison of magnetic resonance elastography and shear wave elastography in the same individuals.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Hyun Sik Woo; Mi Hye Yu; Ijin Joo; Eun Sun Lee; Ji Young Sohn; Kyung Boon Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

10.  Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

Authors:  Mi Sung Park; Beom Kyung Kim; Jae Yoeun Cheong; Dong Joon Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Seung Up Kim
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.